Article

Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimer’s disease

2024-07-23

Abstract excerpt

<h4>ABSTRACT</h4> Rates of cognitive decline in Alzheimer’s disease (AD) are extremely heterogeneous, with ages of symptom onset ranging from age 40-100 years and conversion from mild cognitive impairment to AD dementia taking 2-20 years. Development of biomarkers for amyloid-beta (Aβ) and tau protein aggregates, the hallmark pathologies of AD, have improved patient monitoring/stratification and drug development,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: df3a7728-e4fe-5eae-ba2e-05e6db2e98c3
DOI: 10.1101/2024.07.22.604680

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimer’s diseaseDOI 10.1101/2024.07.22.604680Read

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read

Multiplex plasma profiling of synaptic biomarkers in Alzheimer’s disease using NULISA: early alterations, APOE genotype effects, and pTau217 associationsSemantic proximity Read

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseasesSemantic proximity Read

Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersSemantic proximity Read

CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panelsSemantic proximity Read

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.Semantic proximity Read

Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity Read

Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotypeSemantic proximity Read

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read

A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity Read

CSF proteogenomics implicates novel proteins and humoral immunity in Alzheimer’s disease riskSemantic proximity Read

Proteomic Signatures of Neuropathological Alterations in Alzheimer’s Disease: Insights from the Bio-Hermes StudySemantic proximity Read